** Shares of drugmaker Phathom Pharmaceuticals PHAT.O rise 134% to near 7-month high of $11
** Co's request to the US FDA to update the "Orange Book" has been approved, granting its stomach infection medication, Voquezna, a 10-year exclusivity period
** Stock set for its best day on record, if gains hold
** The exclusivity period will prevent other firms from making similar versions of Voquezna
** Phathom filed a citizen petition to the FDA last year, seeking this exclusivity
** This exclusivity was initially granted to other versions of the drug, Voquezna Paks, which contain the same active ingredient as Voquezna
** Exclusivity protection will extend through May 3, 2032
** Including session's moves, stock up 31% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.